0
Articles |

Proventil HFA Provides Bronchodilation Comparable to Ventolin Over 12 Weeks of Regular Use in Asthmatics

Eugene R. Bleecker; David G. Tinkelman; Joe Ramsdell; Bruce P. Ekholm; Nancy M. Klinger; Gene L. Colice; Herbert B. Slade
Author and Funding Information

Affiliations: From the Department of Medicine, University of Maryland, Baltimore,  From the National Jewish Medical and Research Center, Denver,  From the UCSD Medical Center, San Diego,  From the 3M Pharmaceuticals, St. Paul, Minn.

Affiliations: From the Department of Medicine, University of Maryland, Baltimore,  From the National Jewish Medical and Research Center, Denver,  From the UCSD Medical Center, San Diego,  From the 3M Pharmaceuticals, St. Paul, Minn.

Affiliations: From the Department of Medicine, University of Maryland, Baltimore,  From the National Jewish Medical and Research Center, Denver,  From the UCSD Medical Center, San Diego,  From the 3M Pharmaceuticals, St. Paul, Minn.

Affiliations: From the Department of Medicine, University of Maryland, Baltimore,  From the National Jewish Medical and Research Center, Denver,  From the UCSD Medical Center, San Diego,  From the 3M Pharmaceuticals, St. Paul, Minn.


1998 by the American College of Chest Physicians


Chest. 1998;113(2):283-289. doi:10.1378/chest.113.2.283
Text Size: A A A
Published online

Abstract

Objective: To compare the bronchodilator effectiveness of albuterol reformulated in the chlorofluorocarbon-free propellant hydrofluoroalkane (HFA)134a (Proventil HFA) to that of Ventolin and HFA placebo over 12 weeks of regular dosing.

Design: Randomized, double-blind, double-dummy, parallel group, placebo-controlled, multicenter trial of asthmatics requiring inhaled β-adrenergic bronchodilators for symptom control.

Interventions: Treatment qid with Proventil HFA, Ventolin, or HFA-134a placebo for 12 weeks.

Measurements: At weeks 0, 4, 8, and 12, spirometry was performed predose and serially over 6 h after dosing with study drug. Bronchodilator efficacy variables, based on FEV1 response to study drug, were proportion of responders, time to onset of effect, peak percent change, time to peak effect, duration of effect, and area under the curve (AUC).

Results: Demographic and baseline characteristics were similar for patients randomized to Proventil HFA (193), Ventolin (186), and HFA-134a placebo (186). No significant differences were found between the Proventil HFA and Ventolin treatment groups for any FEV1 efficacy variable, either predose or during 6 h of serial spirometry, at weeks 0, 4, 8, and 12. For all efficacy variables, except time to onset of effect, the Proventil HFA and Ventolin results were significantly greater than placebo. Time to onset of effect for the HFA-134a placebo group is misleading; only 13 patients (7%) were found to be responders in the intent-to-treat database. These efficacy results were found to be consistent across subgroup analyses of inhaled and nasal corticosteroid use, age (18 to 35 and 36 to 66 years), sex, race, weight (<60, 60 to 100, and >100 kg), and baseline FEVl (≤55% and >55% predicted). The peak FEV1 effect, duration of FEV1 effect, and AUC for FEV1 were all significantly smaller at weeks 4, 8, and 12 than week 0 for both the Proventil HFA and Ventolin treatment groups.

Conclusions: Proventil HFA provided bronchodilation comparable to Ventolin and superior effects to HFA-134a placebo over 12 weeks of regular dosing. There was a diminution in bronchodilator response to both Proventil HFA and Ventolin after 4 weeks of use.


Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543